Zayd Alhaddad, MBBS

Zayd Alhaddad practices at Medstar Union Memorial Hospital in Rosedale, Maryland.

Zayd Alhaddad's NPI, 1467039255, was assigned on March 26, 2021. Zayd Alhaddad holds Maryland license D0099035.

Zayd Alhaddad's primary practice is Medstar Union Memorial Hospital, at 9000 Franklin Square Dr, Rosedale, MD 21237 in Baltimore County. The practice phone is (410) 554-2228.

Zayd Alhaddad's primary practice is Medstar Union Memorial Hospital in Rosedale, Maryland. The medical group on file is MedStar Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Zayd Alhaddad practices. Vendor and product names are available with a free account.

Internal medicine is Zayd Alhaddad's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Zayd Alhaddad is licensed in Maryland.

CMS data shows 290 Medicare services from Zayd Alhaddad across 3 procedure codes in 2024, for 65 Medicare patients. Medicare paid $29,056 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 65 Medicare patients who saw Zayd Alhaddad in 2024. The largest group is 65 to 74, with 28 patients. 75% of them have heart failure, and 75% have high blood pressure. 34% are also on Medicaid. Their average risk score is 2.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Zayd Alhaddad's median patient age at 75, with 40% women.

In 2024, Zayd Alhaddad wrote 148 Medicare Part D claims for 41 patients. 90% of them were for generic drugs. CMS names the drug for 53 of them, across 3 drugs with 11 or more claims each, at $404 in total drug cost. In 2023, CMS named 29 claims across 2 drugs.

Dmand AI links 4 papers to Zayd Alhaddad, published from 2022 to 2024. 2022 was the busiest year, with 2. Zayd Alhaddad's most frequent co-authors are Fady Hany Naguib Iskander, MD and Nripesh Regmi, MD.

CMS Open Payments shows 23 general payments to Zayd Alhaddad from 13 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Alnylam Pharmaceuticals Inc. paid the most, $139.